13.

Advance from investors

 

During the year ended December 31, 2025, we had no advances from investors.

 

During the year ended December 31, 2024, we received advances from investors of approximately US$1.08 million. On August 23, September 5, September 6, September 25, 2024, we entered into a securities purchase agreement with each of four investors (including one member of our Board of Directors), respectively, pursuant to which each purchaser agreed to purchase 89,606 shares of common stock for an aggregate purchase price of US$268,818. On the date that each securities purchase agreement was signed, each purchaser entered into a lock-up agreement with the Company, respectively, whereby each purchaser agreed not to transfer the shares until the six-month anniversary of the date of each securities purchase agreement.

 

The number of shares have been restated in this note to reflect the effect of the 1-for-4 reverse stock split on September 30, 2024, see Note 4(l).

Historical Timeline

Fiscal YearFiled
2025Mar 31, 2026Showing above
2024Apr 15, 2025

About Debt Disclosures

Debt disclosures detail a company's borrowing structure — the types of instruments, interest rates, maturity schedule, and covenant restrictions that define its financial obligations and flexibility. This section is essential for assessing refinancing risk, interest rate exposure, and the margin of safety against financial distress.

Key signals: the maturity schedule reveals concentration risk — large maturities within 1-2 years during tight credit markets can force dilutive refinancing or asset sales. Compare the fair value of debt against carrying amount to gauge whether the market views the company's credit risk differently than the balance sheet suggests. Watch covenant compliance disclosures for tightening cushions, especially leverage and interest coverage ratios. Variable-rate debt exposure quantifies sensitivity to interest rate changes. Secured versus unsecured mix affects recovery rates and future borrowing capacity. Compare net debt-to-EBITDA against industry peers and covenant limits to assess financial health.